Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Cells that are "mismatch repair-deficient" (MMR-D) or "microsatellite instability-high" (MSI-H) are unable to repair mistakes made during cell growth. Women with MMR-D/MSI-H endometrial cancer tend not to respond well to the chemotherapy they receive after surgery. Researchers are exploring the use of the immunotherapy TSR-042 (also called dostarlimab) as an alternative to chemotherapy. Radiation therapy is also used after surgery for endometrial cancer.
Researchers want to find the best doses of BNT324 and BNT327 when given together to treat lung cancer. The people in this study have lung cancer that spread and came back or got worse after treatment.
Researchers want to find the best dose of FOG-001 to use in people with advanced cancer. This study focuses on people who have colorectal and other digestive cancers that spread and keep growing after treatment.
Venetoclax blocks Bcl-2, a protein that helps cancer cells survive and resist the effects of anti-cancer treatments. By blocking Bcl-2, venetoclax may cause the death of cancer cells or make them more sensitive to other treatments. It is taken orally (by mouth).
This study is comparing the effectiveness of combination chemotherapy plus tucatinib and trastuzumab versus combination chemotherapy alone in people with metastatic colorectal cancer that is positive for the HER2 protein. The combination chemotherapy is called mFOLFOX6 (oxaliplatin, leucovorin or levoleucovorin, and fluorouracil) and it is a standard treatment for advanced colorectal cancer.
The purpose of this study is to assess the safety and effectiveness of the investigational immunotherapy LN-145 in patients with non-small cell lung cancer (NSCLC) that has metastasized despite prior treatment. LN-145 is called "autologous tumor infiltrating lymphocytes" (TIL) therapy. It activates white blood cells to attack the tumor.
Researchers are assessing a personalized cancer vaccine called V940 plus pembrolizumab immunotherapy to prevent lung cancer recurrence. The people in this study had surgery to remove non-small cell lung cancer (NSCLC), followed by chemotherapy.
In this study, researchers are comparing a combination of two new drugs with standard treatment for ovarian cancer. The two drugs are avutometinib and defactinib. The people in this study have low-grade serous ovarian cancer that came back after treatment.
Researchers are comparing ivonescimab with pembrolizumab immunotherapy for the initial treatment of advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that has metastasized (spread).
Atezolizumab and durvalumab are standard drugs used to treat small cell lung cancer (SCLC). Researchers want to see if adding iadademstat to standard treatment helps slow SCLC growth longer than standard immunotherapies alone. The people in this study have SCLC that spread outside the lung or to other parts of the body.
